mTORC1 activation in childhood ependymoma and response to sirolimus
- First Online:
- Cite this article as:
- Bowers, D.C., Kucejova, B., Margraf, L. et al. J Neurooncol (2011) 103: 797. doi:10.1007/s11060-010-0455-7
Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient’s tumor.